Bernie - I totally agree about the short lived gains. I picked PCYC and ONXX because I think they may show longer gains sparked by a little good news out of the meeting. OXGN was a flash in the pan and very short lived just as you noted.
Diabetes Market: Eli Lilly's Classic Pharma Vs. Sanofi Aventis' Modern Synergy [View article]
Hi Moedoc, Thank you for the comment. You are correct that Tradjenta is not the first DPP-IV, but the first one in its class to come as a one dose formulation. My apologies if the wording in the article was confusing. Teva does have an agreement to license Actos beginning at the end of 2012 http://bit.ly/AuEMF4 I agree with you about the role of physicians. Novo will certainly provide interesting competition.
Isis: If Trend Holds True, Watch For A Leap After Earnings [View article]
The conference call oozed with confidence and the financials for next year shouldn't disappoint even if Kynamro runs into trouble. Operating costs should be down due to Kynamro's progress to the end of clincal stages. Milestone payment opportunities from various partners and future banking on Kynamro have investors optimistic.
Peter, thank you for your input. I don't doubt the technology whatsoever. I just don't think that the EDAP gain this week will sustain. Long term, stocks with this technology will benefit in my opinion however.
The Coming Vehicle Fuel Cell Revolution [View article]
You are absolutely correct about the Prius release dates for the 1st generation model. The 2nd generation model was released in 2003-2004 and was more widely sold. I was referencing that model. Re-reading upon your comments, I see the confusion. My apologies and I will be submitting a correction regarding the model/date. Thank you.
3 Biotech Stocks With Key FDA Summer Dates [View article]
3 Biotech Stocks With Key FDA Summer Dates [View article]
ASCO Stocks To Consider This Week [View article]
Thanks for the comment!
3 Biotechs To Watch This Week [View article]
Friday's U.S. Top Gainers Have A Biotech Flavor [View article]
5 Year Projection: Here Comes The Sun? [View article]
Diabetes Market: Eli Lilly's Classic Pharma Vs. Sanofi Aventis' Modern Synergy [View article]
Thank you for the comment. You are correct that Tradjenta is not the first DPP-IV, but the first one in its class to come as a one dose formulation. My apologies if the wording in the article was confusing. Teva does have an agreement to license Actos beginning at the end of 2012 http://bit.ly/AuEMF4
I agree with you about the role of physicians. Novo will certainly provide interesting competition.
Cashing In On Diabetes: Novel Approaches [View article]
Thanks for the reply. I may possibly consider a position in the future, but not within 72 hours.
Isis: If Trend Holds True, Watch For A Leap After Earnings [View article]
Solar And Fuel Cell Plays To Consider Now [View article]
The Giants, Ravens And 49ers Of Biotech [View article]
Interesting list! I'm not familiar with which company Salk is in talks with.
EDAP's Move Likely Short Lived [View article]
The Coming Vehicle Fuel Cell Revolution [View article]
The Coming Vehicle Fuel Cell Revolution [View article]
Thank you for the comments and thoughts on this article. It's good to see all the dialog on this issue.
The Giants, Ravens And 49ers Of Biotech [View article]